The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Nov. 19, 2019
Filed:
Feb. 10, 2017
Applicants:
The Katholieke Universiteit Leuven, Leuven, BE;
University Hospital Antwerp, Edegem, BE;
Inventors:
Berten Ceulemens, Westmalle, BE;
Lieven Lagae, Oud Heverlee, BE;
Assignees:
THE KATHOLIEKE UNIVERSITEIT LEUVEN, Leuven, BE;
UNIVERSITY HOSPITAL ANTWERP, Edegem, BE;
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/5513 (2006.01); A61K 31/137 (2006.01); A61K 45/06 (2006.01); A61K 31/135 (2006.01); A61K 31/19 (2006.01); A61K 31/36 (2006.01); A61K 31/551 (2006.01); C12Q 1/6883 (2018.01);
U.S. Cl.
CPC ...
A61K 31/5513 (2013.01); A61K 31/135 (2013.01); A61K 31/137 (2013.01); A61K 31/19 (2013.01); A61K 31/36 (2013.01); A61K 31/551 (2013.01); A61K 45/06 (2013.01); C12Q 1/6883 (2013.01); C12Q 2600/156 (2013.01);
Abstract
A method of treating and/or preventing Dravet Syndrome in a patient such as a patient previously diagnosed with Dravet Syndrome, by administering an effective dose of fenfluramine or its pharmaceutically acceptable salt to that patient. Dravet Syndrome patients are typically children under the age of 18 and are treated at a preferred dose of less than about 0.5 to about 0.01 mg/kg/day.